Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674206 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00674206 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 6 participants.
The verdict
NCT00674206, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if the combination of gemcitabine and oxaliplatin is effective for triple negative breast cancer.
Interventions
- DRUG Oxaliplatin
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674206
The ClinicalTrials.gov registry entry for NCT00674206 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00674206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674206 about?
NCT00674206 is a clinical study titled "A Phase II Trial of Gemcitabine and Oxaliplatin for Triple Negative Metastatic Breast Cancer". The purpose of this study is to investigate if the combination of gemcitabine and oxaliplatin is effective for triple negative breast cancer.
What is the current status of trial NCT00674206?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2008-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00674206?
The interventions under investigation include: Oxaliplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00674206?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.